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Abstract
Background: Serum C-reactive protein (CRP) has been identified in prospective epidemiological
research as an independent risk marker for cardiovascular disease. In this paper, short-term
biological variation of CRP is documented and a strategy to test the reliability of a single CRP
sample is proposed.
Methods: Data were obtained from three groups of healthy volunteers: men, no oral
contraceptives (OC-)using women and OC-using women. Blood samples were obtained 3 times in
men and twice in women during a workweek.
Results and discussion: CRP values were highest in the OC-using women, followed by the men,
and lowest in the no OC-using women. Averaged over the three groups the within-subject
coefficients of variation (CVi) was 49.24% for CRP, and 29.90% for lnCRP. Using the repeated
measures, individual samples were identified that reflected a 'suspicious' unreliable high value, i.e. a
value that was more than 2 standard deviations higher than the lowest value obtained from the
same subject. In an a posteriori analysis, three strategies to identify these suspicious high CRP values
were then tested. In terms of maximizing detection of suspicious values and minimizing unnecessary
resampling, best results were obtained for the most pragmatic criterion of using an absolute level,
stratified for gender, and OC-use, to decide whether a second sample should be obtained.
Conclusion: A single high CRP value must be followed by re-sampling when it is above 1.75 mg/l
for men, above 1.00 mg/l for no OC-using women, and above 2.00 mg/l for OC-using women.
Background
Prospective epidemiological research has identified C-re-
active protein (CRP), for both men and women, as an in-
dependent predictor for cardiovascular diseases (CVD)
[1,2]. Clinical utility of CRP values as diagnostic for CVD
risk awaits a validated classification scheme to convert the
CRP blood value of a single individual into a risk proba-
bility. Three major problems impede development of
such a scheme. First, CRP is highly sensitive to injury and
recent inflammatory events not necessarily related to the
chronic atherosclerotic inflammation. CRP levels can in-
crease to as much as 1–1000 fold from baseline concen-
trations with bacterial infection, trauma, surgery, and
other inflammatory events, declining to baseline level in
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traceptives (OC) use and gender on CRP values, that may
be unrelated to CVD risk. Women using OC have higher
CRP values [4] but are not at more risk for CVD than men
[5]. Third, even within infection-free subjects, stratified
for gender and OC-use, large intra-individual variability
in CRP may be found, as hinted at by our previous results
on acute phase proteins [6]. As long as interindividual var-
iability is large, this need not present a problem, but doc-
umentation of intra- and interindividual variability of
CRP, to our knowledge, is largely limited to two recent
publications [7,8].
A first step in the research presented in this paper was to
collect data on intra-individual variability -or its reverse:
test-retest reliability – in gender and OC-use specific sub-
groups, with no reports of recent infection. As previously
reported, we repeatedly assessed levels of fasting insulin,
high density lipoprotein cholesterol (HDL-C), low densi-
ty lopoprotein cholesterol (LDL-C), triglycerides (TG), fi-
brinogen, tissue-type plasminogen activator (t-Pa)
activity, t-PA antigen, plasminogen activator inhibitor-1
(PAI1) antigen within a single work week in three groups
of healthy subjects separately: men, no OC-using women
and OC-using women [6,9]. CRP has now additionally
been analysed in these samples. A variance components
method was used to evaluate the different sources of vari-
ance of (ln)CRP: analytical, intra-individual and inter-in-
dividual. Intraweek test-retest reliability was computed
over three and five days. As a second step we tested three
different criteria that could be used to determine the ne-
cessity of repeated sampling after a high CRP value was
found in an individual. Using the repeated measures, in-
dividual samples were identified that reflected a "suspi-
cious" unreliable high value, i.e. a value that was more
than 2 standard deviations (SD) higher than the lowest
CRP value obtained from the same subject. We then at-
tempted to detect this suspicious value in an a posteriori
analysis in which all samples were regarded to come from
a (typical epidemiological) study design with only one
blood sample available per subject. Three different criteria
were used: (1) The first criterion was to label all values
above an arbitrary absolute threshold level as an unrelia-
ble sample. (2) Second, we used an individual's predicted
CRP value as a criterion. The individual CRP values were
predicted from known correlates like gender, BMI, smok-
ing behaviour and alcohol consumption [4,10]. (3) Final-
ly, we used a similar regression procedure to obtain a
predicted CRP value, this time adding fibrinogen and the
full spectrum of metabolic syndrome X risk indicators (in-
sulin, HDL-C, LDL-C, TG, t-PA antigen, t-PA activity, and
PAI-1 antigen) obtained in the same blood sample as ad-
ditional predictors. Recent studies suggest that CRP
should be included in the insulin resistance (IR) syn-
drome cluster, since both elevated CRP levels and IR have
been found to be markers of the presence of infections,
and inflammation in the vessel wall with atherosclerosis
[11,12]. We reasoned that future clinical CVD risk assess-
ment may increasingly measure various parameters of the
metabolic syndrome in a single blood sample. Thus, we
explored the possibility that multivariate measures could
help decide on the reliability of an observed CRP value as
an alternative for the classic multiple sampling procedure.
In all instances, criteria for resampling were evaluated sep-
arately for men, no OC-using women and OC-using
women.
Methods
Subjects
In the present study, 92 male clerical workers from a large
computer company (mean age 45.2 ± 5.3 years, range 35–
55 years; BMI 25.1 ± 2.8) and 132 female nurses from
three hospitals (mean age 33.7 ± 8.0 years, range 22–55
years; BMI 23.9 ± 4.0) volunteered to participate in cardi-
ovascular risk assessment. Subjects were included only if
healthy, non-pregnant, not receiving treatment or taking
medication for hypertension, known to suffer from cere-
brovascular disease, hyperlipidaemia or diabetes mellitus.
Also subjects who had used aspirin or other anti-inflam-
matory or analgesic medication were excluded from the fi-
nal analyses. One of the female subjects had CRP levels >
10 mg/l on both occasions (15.94 and 16.26, respective-
ly). She reported having used diet pills before both blood
withdrawal days and was therefore excluded from the fi-
nal analyses. All subjects gave written informed consent
before entrance to the study. Study and blood sampling
protocol were approved by the Ethics Committee of the
Vrije Universiteit, Amsterdam.
Procedure
Because most blood variables are known to respond to a
host of confounders (e.g. time of day, shift work, current
or previous day meals, alcohol or coffee drinking and
physical activity etc.) rigid standardization of blood sam-
pling procedures was enforced to optimize test-retest reli-
ability. Subjects were requested to fast and refrain from
use of alcohol, coffee and tea after 11:00 p.m. the preced-
ing night and to refrain from high impact physical activity
the preceding day. In both the male and the female popu-
lation blood was drawn at the workplace from the arm in
a sitting position after at least 15 minutes rest. In the male
population blood was drawn on Monday, Wednesday
and Friday, at the beginning of a workday, between 8:00
and 9:30 a.m. In the nurses, blood was drawn solely at
daytime shifts, between 7:00 and 7:30 a.m. Nurses had to
work at least three successive daytime shifts and the first
measurement day had to be preceded by at least two non-
working days, (to make sampling comparable to the Mon-
day measurement in the male population). The first blood
sample was drawn at the first day of a daytime shift, andPage 2 of 12
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comparable to the Wednesday measurement in the male
population) when the nurses were still on a daytime shift.
After the first blood sample was drawn, subjects' body
weight (to the nearest 100 g.) and height (to the nearest
cm.) were measured in light clothing.
Metabolic risk indicators
Blood withdrawal was according to the standardized Eu-
ropean Concerted Action on Thrombosis (ECAT) assay
procedures [13,14]. Blood was drawn by venipuncture of
the antecubital vein and sampled in six different vacutain-
ers in the following order; serum with clot-activator (5
ml), serum (3 ml), stabilyte® (5 ml), citrate (5 ml), EDTA
(3 ml), NaF (2 ml). All vacutainers were mixed directly af-
ter sampling by inverting them 5 times. Fasting insulin
(pmol/l) was determined with an immunoradiometricas-
say kit (Medgenix Diagnostics Fleurus, Belgium) from
blood taken out of the serum-vacutainer. Blood had to
clot for 60 minutes at room temperature. Serum was sep-
arated by centrifugation at 2,000 × g for 20 minutes at
4°C. Aliquots of serum were stored at -20°C. Values were
multiplied by 0,139 to convert fasting insulin into mU/l.
For determination of total cholesterol (TC), triglyceride
(TG), and high-density lipoprotein cholesterol (HDL-C)
the serum of the clot-activator vacutainer was used. Blood
was allowed to clot for 30–120 minutes at room temper-
ature. Serum was separated by centrifugation at 2,000 × g
for 20 minutes at 4°C. Lipid determinations were per-
formed at the same day using the Vitros 250 Clinical
Chemistry analyser (Johnson & Johnson, Rochester, USA)
with Vitros clinical chemistry slides for TC and TG. HDL-
C was determined in serum after a precipitation step with
HDL-C percipitant (Boehringer Mannheim, Mannheim,
Germany). LDL-C was calculated according to the formula
of Friedewald [15]. All lipid values are given in mmol/l.
Stabilyte blood was drawn for the determination of tissue-
type plasminogen activator activity (tPA-Act). Citrated
blood was withdrawn for determination of CRP, fibrino-
gen, tissue-type plasminogen activator antigen (tPA-Ag)
and plasminogen activator inhibitor-1 antigen (PAI-1-
Ag). Immediately after withdrawal, the vacutainers were
put in melting ice and centrifuged within 60 minutes
(2.000 × g, 20 minutes at 4°C). Aliquots of plasma were
snap-frozen immediately using solid carbon dioxide and
stored at -80°C. tPA-Act was measured using the biofunc-
tional immunosorbent assay Chromolize™tPA (Biopool,
Umeå, Sweden). Results were expressed in IU/ml. Fibrin-
ogen was determined using the STA coagulation analyser
(STAG-O, Asnières, France) and the STA Fibrinogen kit
(Boehringer Mannheim, Germany). The results are ex-
pressed in g/l. tPA antigen was measured using the en-
zyme immunoassay Imulyse™tPA (Biopool, Umeå,
Sweden). PAI-1-Ag was measured using enzyme immu-
noassay Innotest PAI-1 (Innogenetics, Zwijndrecht, Bel-
gium). Results of tPA-Ag and PAI-Ag are expressed in ng/
ml. C-reactive Protein (CRP) was measured using a sensi-
tive enzyme immunoassay. Briefly, polystyrene microtit-
erplates were coated with a polyclonal antibody against
human CRP (DAKO A/S, Glostrup, Denmark). Test sam-
ples were incubated in a 1000 times dilution for 2 hrs at
room temperature. After a washing procedure, detecting
antibody solution was added (peroxidase labelled poly-
clonal antibodies against human CRP, DAKO A/S, Glos-
trup, Denmark). After a 1 hr incubation at room
temperature, the microtiterplate was washed and sub-
strate solution was added. After a 15 minutes incubation
period at room temperature the reaction with substrate
was stopped with the addition of sulphuric acid. The col-
our development was recorded spectrophotometrically
and the CRP content of the test sample was calculated
from the calibration curve. Standard CRP serum (Dade
behring, Marburg, Germany) was used for calibration,
which was calibrated against the international standard
for CRP (WHO-code 85/506). Results of CRP are ex-
pressed in mg/l. The reference range for healthy individu-
als of the method used is 2.5 – 97.5% content interval:
0.07 – 5.25 mg/l. The intra-assay coefficient of variation at
different points within the reference range were 2.4% for
CRP concentrations < 0.5 mg/l, 1.8% for CRP concentra-
tions between 0.5–2.5 mg/l, 1.8% for CRP concentrations
between 2.5–5.5 mg/l, and 3.1% for CRP concentrations
higher than 5.5 mg/l. The intra-assay and inter-assay coef-
ficient of variation were less than: 5.0 and 7.0 % for fast-
ing insulin, 4.0 and 6.0 % for TC, 3.5 and 5.0 % for HDL-
C, 3.0 and 5.0 % for TG, 5.0 and 7.0 % for fibrinogen,
10.0 and 12.0 % for tPA-Ag, 7.5 and 10.0 % for tPA-Act,
10.0 and 10.0 % for PAI-1-Ag, 2.0 and 10.0 % for CRP. For
each of the blood variables the samples were analyzed in
the same batch. Moreover, the blood samples, drawn
from the same subject on repeated blood withdrawal oc-
casions, were analyzed simultaneously on the same plate.
No sample had been stored for more than seven months.
Behavioural risk factors
Smoking behaviour was assessed as number of cigarettes
smoked a day. Alcohol consumption was assessed as
number of glasses consumed per week in 7 categories
which were: less than 1 glass (1), 1–2 (2), 3–5 (3), 6–10
(4), 11–20 (5), 21–40 (6), and more than 40 glasses a
week (7). Oral contraceptive use was assessed on the first
blood withdrawal session and nurses were categorised as
non users (0) or users (1).
Statistical analyses
Analyses of intra-week effects and group differences were
performed in a repeated-measurement General Linear
Modelling (GLM, SPSSWin 9.0) procedure using the data
obtained from the first two withdrawal days of all sub-
jects. The dependent variable in the GLM model was CRP.Page 3 of 12
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(lnCRP) to meet the demands of normal frequency distri-
bution. Men, no OC-using women and OC-using women
were entered in the model as between subject factor. Age
and BMI were entered as covariates in the analyses. The
GLM procedure was started with a model specification,
which included all main effects and all second, and third
order interactions. Subsequently non-significant interac-
tions were removed from the model specification and the
GLM procedure was performed again. This step down pro-
cedure ends when an exclusive significant interaction or a
main effect is found [16].
Test-retest reliability was assessed by 1) computing Pear-
son correlation coefficients and 2) by a method described
in Fraser, and Harris [17] and Marckmann et al. [18] using
the assay variation in the duplicates and the variation
across different measurement days, to obtain estimates of
analytical variance (Sa), average within-subject variance
(Si) and between subject variance (Sg). Analytical variance
was extracted from the variance in the duplicates (as re-
flected in the intra-assay coefficient of variation (CV)).
Based on the criteria of Cotlove, Harris, & Williams [19]
repeated in Fraser et al. [17] and adopted by the college of
American Pathologists and the World association of soci-
eties of pathology, we specify the minimally acceptable
CV for each of the assays (the CV of the assay should equal
to or less than half of the normal intra-week biological
variation also expressed as a CV).
Using the repeated measures, individual samples were
identified that reflected a "suspect" high value, i.e. a value
that was more than 1.96 standard deviations (SD) higher
than the lowest value obtained from the same subject. The
√ Si, calculated as described above, was used as the group
specific SD in this procedure. A posteriori all samples were
then treated as coming from a study design with only one
single blood sample for all subjects, i.e. a typical epidemi-
ological study. Three strategies were then used to see
whether the "suspicious" high CRP values could be detect-
ed in such an epidemiological setting. This means that for
the 75 no OC-using women who gave blood twice all 150
CRP values were used as if they were a single sample that
needs to be diagnosed as reliable, and for the 92 men all
276 CRP values. The first (1) criterion was to label all val-
ues above an arbitrary absolute threshold level as suspect.
Second (2), we used an individual's predicted CRP value
as a criterion. The individual CRP values were predicted
from known correlates like gender, BMI, smoking behav-
iour (in cigarettes a day) and alcohol consumption (in
categories indicating glasses consumed a week). We used
lnCRP because regression analysis demands normal fre-
quency distribution. Subsequently for all values an ex-
pected lnCRP value was calculated. This individual lnCRP
value was back-transformed to a simple non-transformed
CRP value. The difference between the actually measured
CRP level and expected CRP was computed and a thresh-
old level above which a difference between these two val-
ues cannot be considered reliable anymore was
computed. Third (3), we used a similar regression proce-
dure as described above to obtain a predicted CRP value,
this time including fibrinogen and the full spectrum of
metabolic syndrome X risk indicators (insulin, HDL-C,
LDL-C, TG, fibrinogen, t-PA antigen, t-PA activity, and
PAI-1 antigen), as obtained in the same blood sample as
well.
Results
Data was checked with regard to frequency distribution.
Like CRP, insulin, TG, fibrinogen, t-PA antigen, t-PA activ-
ity, PAI-1 antigen were transformed to normal distribu-
tion by natural logarithmic transformation and age and
BMI by 10log logarithmic transformation before entering
into statistical analysis, unless otherwise indicated. For
readability, means and ranges of the variables are given in
Table 1, for the 3 groups separately.
Table 1: Age, BMI and risk indicators for men, no-oral contraceptives (OC) using women and oral contraceptives using women for each 
blood withdrawal day separately (means and ranges are given)
Men (n = 92) No OC-using women (n = 75) OC-using women (n = 56)
Age (years) 45.22 (35–54) 37.1 (23 – 55) 30.0 (22 – 49)
BMI (kg/m2) 25.17 (18.70 – 34.11) 24.4 (18.3 – 40.6) 23.2 (18.2 – 35.6)
Smoking (#/day) 3.28 (0 – 35) 3.41 (0 – 25) 3.68 (0 – 25)
Alcohol use (cat.) 3.64 (1 – 6) 2.28 (0 – 6) 2.25 (0 – 6)
Blood values day 1 day 3 day 5 day 1 day 3 day 1 day 3
Mean CRP (mg/l) 1.22 1.12 1.19 0.83 0.80 2.04 1.86
Range CRP (mg/l) 0.04–4.88 0.02–6.53 0.07–7.98 0.05–3.00 0.05–3.78 0.16–5.58 0.14–4.60
(Note: BMI = body mass index; CRP = C-reactive protein)Page 4 of 12
(page number not for citation purposes)
BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/9Intra week changes and group differences in absolute lev-
els
Values on CRP obtained at day 1 and day 3 were tested for
group differences across men, no OC-using women and
OC-using women. CRP levels did not differ over the days.
On average CRP values differed between the groups
(F(2,230) = 23.19, p < 0.001). Pairwise comparison in
this first multivariate group test showed that OC-using
women had higher CRP values than men (p < 001) and no
OC-using women (p < 0.001), and that men had higher
CRP values than no OC-using women (p = 0.025). Includ-
ing age and BMI as covariates in this analysis did neither
change this group effect (F(2,219 = 36.54, p < 0.001) nor
revealed interaction effects between group and age or
group and BMI. Pairwise comparison in this second mul-
tivariate group test showed that OC-using women had
higher CRP values than men (p < .001) and no OC-using
women (p < 0.001), and that men had only slightly higher
CRP values than no OC-using women (p = 0.096). In the
latter analysis, higher CRP levels were found in subjects
with higher BMI's (F(1,219) = 45.21, p < 0.001), but no
effects of age.
Test-retest reliability
Test-retest correlations between day 1 and day 3 in men
and women, and correlations between day 3 and 5 and
between day 1 and day 5 in men for (ln)CRP are given in
table 2. All correlations were highly significant (p < 001).
Higher correlations were found for lnCRP than for non-
transformed CRP values. For lnCRP the 3-day test-retest
correlation was 0.73 for men, 0.80 for OC-using women
and 0.82 for no OC-using women. In men, the additional
5-day test-retest correlation was 0.60.
As is shown in Table 3, lnCRP correlated highly with BMI
and fibrinogen in all three groups and with t-PA activity
and PAI-1 antigen in men and no OC-using women, but
less with lipids and insulin. Correlation of lnCRP to age
was absent or weak in all groups.
Following Fraser et al. [17] we computed the components
of variance due to between subject variance, within-sub-
ject variance (excluding analytical variance) and analytical
variance (see Table 4) for CRP and lnCRP. Variation esti-
mates were made on both scales for comparative purpos-
es. To check on the analytical precision of (ln)CRP, we
additionally report the intra-assay coefficient of variation
(CV) that is minimally required to reliably detect intra-
week within-subject variance (CVanalytical ≤ 0.5 * CVwithin-
subject)[19]. In all three groups the analytical precision of
(ln)CRP is excellent. However, the within subject coeffi-
cients of variation (CVi) varied between 33.39–67.17
(49.24 on average) for CRP, and between 19.89–39.69
(29.90 on average) for lnCRP, which is substantially high-
er than for e.g. HDL-C and LDL-C [6]. Note that although
the absolute values of the different variance components
are higher in the untransformed CRP values (as expected,
and previously reported by Ockene et al., [8]), but that the
ratio of the three variance components (Sg, Si, and Sa), is
very similar for CRP and lnCRP.
Strategies to assess individual CRP levels reliably
Using the repeated measures, individual samples were
identified that reflected a "suspicious" unreliable value,
i.e. a value that was more than 2 standard deviations (SD)
higher than the lowest value obtained from the same sub-
ject. In figure 1,2,3 graphical representations of the so-de-
fined suspicious values in the three groups are given.
Absolute values
When all suspicious deviants have to be identified by an
absolute criterion, the absolute value has to be different in
the three groups (see table 5). The decision to make sure
all suspicious deviants are identified, implies that many
subjects need to be invited for resampling; 14 (=15 %) in
men, 34 (=24 %) in no OC-using women, and 40 (=38 %)
in OC-using women. In order to find a criterion with a
more favourable trade-off a second strategy using a regres-
sion approach was explored.
Regression analyses
For the second strategy multiple (stepwise) regression
analyses were used. As is shown in table 6, age, BMI,
Table 2: Test-retest correlations for men, no-oral contraceptives (OC) using women and oral contraceptives using women (all p < .001)
Men (n = 92) No OC-Using 
Women (n = 75)
OC-using 
Women (n = 57)
Risk Factors day 1-day 3 Day 3-day 5 day 1-day 5 day 1-day 3 day 1-day 3
CRP .78 .69 .55 .76 .75
LnCRP# .73 .76 .60 .82 .80
(Note; CRP = C-reactive protein; # = transformed to normal distribution before entered into the analyses)Page 5 of 12
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to predict CRP level. However, the amount of explained
variance was to low to further explore this strategy.
Next multiple (stepwise) regression analyses were per-
formed wherein besides age, BMI, smoking behaviour and
alcohol consumption, also the full spectrum of metabolic
syndrome X risk indicators (insulin, HDL-C, LDL-C, TG,
fibrinogen, t-PA antigen, t-PA activity, and PAI-1 antigen),
were used to predict CRP level. As is shown in table 7, the
amount of explained variance varied between 45–51% in
the three groups which was considered high enough to
continue with this third strategy.
Using the regression weights, as given in table 7, predicted
CRP values for all blood samples were calculated. Then
the actually measured (or observed) CRP value was sub-
tracted from this predicted value and used as a criterion to
decide whether a suspicious unreliable deviant is correctly
indicated as unreliable. As is shown in table 8, the criteri-
on necessary to detect all suspicious unreliable deviants
differed between men, no OC-using women and OC-us-
ing women. The number of subjects that are indicated as
having an unreliable CRP sample and need to be invited
for resampling is; 29 (=11 %) in men, 42 (=30 %) in no
OC-using women and 46 (=43 %) in OC-using women.
These numbers, compared to the numbers obtained when
Table 3: Correlations between blood levels of C-reactive protein, and body mass index, age, and parameters of the insulin resistance 
syndrome. Results are given for men, no-oral contraceptives (OC) using women and oral contraceptives using women, separately (sig-
nificant correlations are given in bold face; * p < .05; ** p < .01).
C-reactive protein#
Men No OC-using women OC-using women
day 1 day 3 day 5 day 1 day 3 day 1 day3
Age# -.10 -.11 -.12 .20 .29** -.10 -.04
BMI# .16 .24* .28** .52** .55** .49** .51**
insulin# .06 .10 .27** .20 .19 .25 .21
TC .13 .08 .15 .11 .02 .19 .16
LDL-C .23* .05 .14 .21 .13 .10 .08
HDL-C -.26* -.13 -.21 -.31** -.22** .05 .10
TG# .10 .21* .28* .26* .10 .29* .22
Fibrinogen# .62** .66** .70** .54** .56** .56** .56**
t-PA antigen# .14 .14 .27* .35** .33 .08 .18
t-PA activity# -.21* -.26* -.38** -.36** -.32** .16 -.14
PAI-1 antigen# .20 .28** .41** .42** .39** -.04 .24
(Note: BMI = body mass index; HDL-C = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol; PAI-1 = plasminogen 
activator inhibitor-1;t-PA= tissue-type plasminogen activator; TC = total cholesterol; TG = triglycerides; # = transformed to normal distribution 
before entered into the analyses).
Table 4: Estimates of between subject (BS), within subject (WS) and analytical (A) variation (percentages of total variance in brackets), 
and coefficients of variation (CV) of CRP for men (nind = 92, nobs = 552), non-oral contraceptives (OC) using women (nind = 75, nobs = 
300) and oral contraceptives using women (nind = 56, nobs = 224), separately.
Between subject Within subject Analytical
Variance (%) CVBS Variance (%) CVWS Variance (%) CVA 1/2CVWS
Men
CRP 1.17 (65.3) 92.20 0.62 (34.6) 67.16 0.00055 (0.03) 2.00 33.58
lnCRP 0.15 (68.8) 57.98 0.068 (31.2) 39.69 0.00017 (0.08) 1.98 19.85
No OC-using women
CRP 0.47 (75.8) 84.51 0.15 (24.2) 47.17 0.00026 (0.04) 2.00 23.59
lnCRP 0.11 (82.0) 65.32 0.024 (17.9) 30.13 0.00011 (0.08) 2.02 15.07
OC-using women
CRP 1.23 (74.5) 56.92 0.42 (25.4) 33.39 0.0015 (0.09) 1.99 16.70
lnCRP 0.15 (79.2) 43.49 0.039 (20.6) 19.89 0.00038 (0.20) 1.98 9.95
(Note: CRP = C-reactive protein; lnCRP = natural logarithmic transformed C-reactive protein; nind = number of individuals; nobs = number of 
observations)Page 6 of 12
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Graphical representation of the identification of the suspicious and not suspicious CRP values in the men (see text for more
information).
Table 5: Calculated sensitivity and specificity of detecting unreliable CRP values using an absolute criterion. Results are given for men, 
no-oral contraceptives (OC) using women, and oral contraceptives using women, separately.
Men No OC-using women OC-using women
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
2.75 mg/l 0.65 0.93 0.60 0.99 0.67 0.78
2.50 mg/l 0.71 0.93 0.60 0.98 0.83 0.74
2.25 mg/l 0.88 0.90 0.70 0.97 0.67 0.78
2.00 mg/l 0.94 0.88 0.70 0.96 1.00 0.62
1.75 mg/l 1.00 0.85 0.80 0.93 1.00 0.52
1.50 mg/l 1.00 0.80 0.90 0.89 1.00 0.45
1.00 mg/l 1.00 0.69 1.00 0.76 1.00 0.29
Men
CRPL (mg/l)
543210-1
C
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H
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in both groups of women.
Discussion
C-reactive protein has been identified in prospective epi-
demiological research as an independent risk factor for
CVD. Using this acute phase protein in risk prediction in
individuals is still under debate. In this paper test-retest re-
liability of CRP and its log-transformed was found to be
adequate; the relative rankings of the subjects remained
fairly constant within one workweek. In addition, study-
ing the variability of (ln)CRP, the CVanalytical was less than
half of the CVwithin subject indicating that the analytical
precision of (ln)CRP is satisfactory as well. On average for
the three studied groups (men, no OC-using women, and
OC-using women), the CVwithin subject found in this paper
is 49.24% for CRP, and 29.90% for lnCRP. This is lower
than the value of 63.0% for CRP reported by Clark et al.,
([20]; in 29 healthy men and women, aged 20–46 years),
and comparable to the value of 42.2%for CRP reported by
Macy et al., ([21]; in 143 healthy men and women; aged
18–67 years), and comparable to the average value of
30% reported in a review of Kluft et al. [7] for lg10 trans-
formed CRP.
Such large biological intra-individual variance makes it
very difficult to decide whether a single blood sample is
an individuals 'true' habitual level. Based on our data, we
advise against classifying a subject as high using a single
CRP sample only, for instance by upper tertiles or quar-
Figure 2
Graphical representation of the identification of the suspicious and not suspicious CRP values in the no oral contraceptives
(OC)-using women (see text for more information).
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BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/9tiles as is common practice for e.g. total cholesterol. In-
stead multiple sampling of CRP within one individual is
necessary. To reduce the number of sampling needed, i.e.
for application in epidemiology-scaled research, and after
Kluft et al. [7] we aimed to provide a criterion to decide
whether a single high sample can be trusted, or whether
resampling is necessary.
Results clearly favour an absolute level criterion. Specifici-
ty and sensitivity were as good as that of the more elabo-
rate regression approach that is more complicated and
expensive since BMI and other metabolic and fibrinolytic
risk indicators for CVD need to be assessed. Different cri-
teria for the three groups (men, no OC-using women and
OC-using women) are needed to decide whether a single
high sample suffices or whether a second sample should
be taken. These group specific values above which resam-
pling of CRP is deemed necessary are 1.75 mg/l for men,
1.00 mg/l for no OC-using women, and 2.00 mg/l for OC-
using women.
How to proceed when a second sample is indeed required
by the criteria above? A pragmatic strategy was suggested
by Kluft et al. [7]: after a first blood sample is diagnosed
as above the criterion, blood sampling should be repeated
no earlier than 2 weeks after the first sample, or later. If the
second sample is below the criterion, the first sample
must be distrusted and the value of the second sample is
more likely to reflect the 'true' value. If the second sample
is again above the criterion, the subject should be regard-
Figure 3
Graphical representation of the identification of the suspicious and not suspicious CRP values oral contraceptives (OC)-using
women (see text for more information).
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ease. He or she needs to be regularly bled for CRP level
monitoring over a prolonged time, possibly accompanied
by in depth medical examination as prompted by the spe-
cific anamnesis of the patient [4,7].
A limitation of this study is that the criteria cannot be gen-
eralised to the general population. Strict inclusion was ap-
plied such that all our subjects were very healthy and free
of chronic diseases like hypertension, CVD, or diabetes.
Additionally, our subjects were young. Sampling in older
subjects with further advanced atherosclerotic inflamma-
tion would certainly have resulted in a larger CRP vari-
ance. Secondly, resampling in the current study took place
within one week. In clinical settings persons ideally are in-
vited for resampling 12–14 days after the first increased
level sample was obtained, when CRP level characteristi-
cally has returned to baseline after a moderate inflamma-
tory stimulus [3]. The positive side of these limitations is
that our criteria are probably too conservative. Multiple
repeated sampling after longer intervals in a larger general
population could certainly sharpen the proposed criteria
such that, in the terminology of this paper, specificity is
increased without loss of sensitivity.
Table 6: Multiple regression analyses (stepwise); predicting 
lnCRP levels (lowest value obtained from 2 or 3 blood withdrawal 
days) entering body mass index (BMI), age, smoking behaviour, 
and alcohol consumption into the regression. Results are given 
for men, no-oral contraceptives (OC) using women, and oral con-
traceptives using women, separately.
Men
Variable β coefficient p-value R2
Constant -1.485 0. 057
Smoking 0.161 0.000 0.211
BMI# 2.646 0.000 0.315
Age# -1.107 0.003 0.338
No OC-using women
Variable β coefficient p-value R2
Constant -3.912 0.000
BMI# 2.623 0.000 0.342
Age# 0.467 0.049 0.359
OC-using women
Variable β coefficient p-value R2
Constant -4.085 0.000
BMI# 3.659 0.000 0.282
(Note; BMI = body mass index; lnCRP = natural logarithmic trans-
formed C-reactive protein; OC = oral contraceptives; # = trans-
formed to normal distribution before entered into the analyses)
Table 7: Multiple regression analyses (stepwise); predicting 
lnCRP levels (lowest value obtained from 2 or 3 blood withdrawal 
days) entering body mass index (BMI), age, smoking, alcohol use 
and the insulin resistance parameters (insulin, total cholesterol, 
HDL-C, LDL-C triglycerides, t-PA antigen, t-PA activity, PAI-1 
antigen) into the regression. Results are given for men, no-oral 
contraceptives (OC) using women, and oral contraceptives using 
women, separately.
Men
Variable β coefficient p-value R2
Constant -2.697 0.001
Fibrinogen# 1.182 0.000 0.325
BMI# 2.306 0.000 0.390
Smoking 0.106 0.000 0.461
Age# -0.975 0.004 0.478
t-PA antigen# -0.141 0.004 0.487
t-PA activity# -0.064 0.016 0.498
LDL-C 0.044 0.031 0.506
No OC-using women
Variable β coefficient p-value R2
Constant -3.613 0.000
BMI# 1.957 0.000 0.344
Fibrinogen# 0.919 0.000 0.452
PAI-1 antigen# 0.108 0.006 0.473
Insulin# -0.136 0.035 0.491
OC-using women
Variable β coefficient p-value R2
Constant -4.246 0.000
Fibrinogen# 1.375 0.000 0.327
BMI# 2.192 0.000 0.411
HDL-C 0.202 0.011 0.445
(Note: BMI = body mass index; HDL-C = high density lipoprotein 
cholesterol; LDL-C = low density lipoprotein cholesterol; lnCRP = 
natural logarithmic transformed C-reactive protein; PAI-1 = plasmino-
gen activator inhibitor-1;t-PA= tissue-type plasminogen activator; # = 
transformed to normal distribution before entered into the analyses).Page 10 of 12
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A single high CRP value must be followed by re-sampling
when it is above 1.75 mg/l for men, above 1.00 mg/l for
no OC-using women, and above 2.00 mg/l for OC-using
women. Using additional information from gender, BMI,
smoking behavior, alcohol use, insulin, HDL-C, LDL-C,
TG, t-PA antigen, t-PA activity, and PAI-1 antigen does not
meaningfully improve on the use of absolute CRP levels
stratified for gender and OC-use.
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